Your browser doesn't support javascript.
loading
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force.
Averna, Maurizio; Banach, Maciej; Bruckert, Eric; Drexel, Heinz; Farnier, Michel; Gaita, Dan; Magni, Paolo; März, Winfried; Masana, Luis; Mello E Silva, Alberto; Reiner, Zeljko; Ros, Emilio; Vrablik, Michal; Zambon, Alberto; Zamorano, Jose L; Stock, Jane K; Tokgözoglu, Lale S; Catapano, Alberico L.
Afiliación
  • Averna M; Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities, University of Palermo, Palermo, Italy.
  • Banach M; Polish Mother's Memorial Hospital Research Institute (PMMHRI) in Lodz, Lodz, Poland.
  • Bruckert E; Pitié-Salpêtrière Hospital and Sorbonne University, Cardio Metabolic Institute, Paris, France.
  • Drexel H; Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein; Drexel University College of Medicine, Philadelphia, PA, USA.
  • Farnier M; PEC2, EA 7460, University of Bourgogne Franche-Comté and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France.
  • Gaita D; Universitatea de Medicina si Farmacie Victor Babes, Institutul de Boli Cardiovasculare, Clinica de Recuperare Cardiovasculara, Timisoara, Romania.
  • Magni P; Department of Pharmacological and Biomolecular Sciences, Universita' degli Studi di Milano, Milan, and IRCCS MultiMedica, Milan, Italy.
  • März W; SYNLAB Academy, SYNLAB Holding Deutschland GmbH, and Medical Clinic V, Medical Faculty of Mannheim, University of Heidelberg, Germany; Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria.
  • Masana L; Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV CIBERDEM, 43201, Reus, Spain.
  • Mello E Silva A; Luz Saúde-Portugal; Sociedade Portuguesa de Aterosclerose, Lisbon, Portugal.
  • Reiner Z; Department of Internal Diseases University Hospital Center Zagreb, School of Medicine, Zagreb University, Zagreb, Croatia.
  • Ros E; Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 08036, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, 28029, Spain.
  • Vrablik M; Third Department of Internal Medicine, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 1, 128 08, Prague 2, Czech Republic.
  • Zambon A; Department of Medicine - DIMED, University of Padua, Padova, and IRCCS MultiMedica, Milan, Italy.
  • Zamorano JL; Department of Cardiology, University Hospital Ramón y Cajal Carretera de Colmenar, Madrid, Spain.
  • Stock JK; European Atherosclerosis Society, Mässans Gata 10, SE-412 51, Gothenburg, Sweden.
  • Tokgözoglu LS; Department of Cardiology, Hacettepe University Faculty of Medicine, Turkey.
  • Catapano AL; Department of Pharmacological and Biomolecular Sciences, Universita' degli Studi di Milano, Milan, and IRCCS MultiMedica, Milan, Italy. Electronic address: alberico.catapano@unimi.it.
Atherosclerosis ; 325: 99-109, 2021 05.
Article en En | MEDLINE | ID: mdl-33892925
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Diabetes Mellitus Tipo 2 / Aterosclerosis / Anticolesterolemiantes Tipo de estudio: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Atherosclerosis Año: 2021 Tipo del documento: Article País de afiliación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Diabetes Mellitus Tipo 2 / Aterosclerosis / Anticolesterolemiantes Tipo de estudio: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Atherosclerosis Año: 2021 Tipo del documento: Article País de afiliación: Italia